Navigation Links
Multi-Center Clinical Study Confirms Decreased Levels of Procalcitonin as an Independent Predictor of Mortality in Patients with Severe Sepsis and Septic Shock
Date:4/19/2017

WALTHAM, Mass., April 19, 2017 /PRNewswire/ -- Thermo Fisher Scientific Inc. today announced that results from the multi-center Procalcitonin MOnitoring SEpsis (MOSES) Study have been published in the May 2017 print issue of Critical Care Medicine. Researchers from the study, titled "Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study," investigated the use of the B·R·A·H·M·S PCT (procalcitonin) assay to assess risk for 28 day all-cause mortality for patients diagnosed with severe sepsis or septic shock in 13 U.S. investigational sites.

Results from the multi-center study showed that patients with a decrease in PCT less than or equal to 80 percent during the first four days following diagnosis of severe sepsis or septic shock had a two-fold increased risk of death as compared to those who experienced a decrease in PCT greater than 80 percent1. The study also found that a baseline PCT measurement greater than 2.0 ng/mL is an additional mortality risk factor when evaluating PCT measurements on subsequent days1.

"Given the significant amount of sepsis-related deaths in the United States, there is a need for a more rigorous and effective approach to monitoring the progression of this syndrome in patients," said lead principal investigator, Nathan I. Shapiro, M.D., MPH, attending physician at the department of emergency medicine at Beth Israel Deaconess Medical Center in Boston. "Through the MOSES study, my fellow investigators and I have gained a better understanding of how serial PCT levels can be measured in a hospital setting to further risk-stratify mortality risk."

"We are proud to partner with Dr. Nathan Shapiro, Dr. Philipp Schuetz, and all the investigators of the MOSES trial, and support their initiatives in securing publication of this study," said Lonnie Shoff, President of the Clinical Diagnostics Division at Thermo Fisher Scientific. "These clinical results further validate and help shed light on the critical role PCT plays in the risk assessment for patients diagnosed with severe sepsis or septic shock. We look forward to continuing the conversation around the importance of sepsis awareness and the impact PCT can have in septic patient management."

As a result of the MOSES study, Thermo Fisher Scientific received expanded FDA clearance for its B·R·A·H·M·S PCT biomarker assay for sepsis risk assessment. Under the expanded clearance, PCT measurements can be obtained in emergency departments and hospital wards prior to admission to the intensive care unit. Additionally, the clearance helped the Thermo Fisher Scientific license partners, Roche Diagnostics USA and bioMérieux to achieve FDA clearance for the Roche ELECSYS B·R·A·H·M·S PCT and bioMérieux VIDAS B·R·A·H·M·S PCT assays in just 90 days, further expanding access to PCT in the United States. Physicians can assess the decrease in PCT levels using the online calculator at www.brahms-pct-calculator.com.

About Sepsis
Sepsis is a systemic inflammatory response to infection with some degree of organ dysfunction that can progress to organ failure and death. Each year, more than 266,000 deaths in the U.S. are attributed to sepsis (2009). It is the sixth most common principal diagnosis in the U.S., accounting for more than 1.6 million hospital stays. It is the most costly inpatient diagnosis, with aggregate annual hospital costs totaling over $23 billion (2013). Early identification and intervention are crucial to improving sepsis outcomes, making rapid, more reliable detection a national, if not global, imperative. To learn more about sepsis, please visit: www.thermofisher.com/aboutsepsis.

About Procalcitonin (PCT)
In healthy people, Procalcitonin (PCT) is produced in thyroid cells as a precursor for the hormone calcitonin and is nearly undetectable in human blood. However, bacterial infections cause PCT to be produced by almost every organ of the body, resulting in a rapid rise of PCT levels in the blood. Viral infections very rarely, and not to the same level, cause this increase in PCT blood levels. The level of PCT in the blood is a reflection of the severity of bacterial infection, ranging from slightly elevated concentrations in infections with minor systemic inflammatory response to very high values in cases of severe sepsis and septic shock. Once an infection is under control, PCT levels decrease rapidly. PCT is intended for use in conjunction with other laboratory findings and clinical assessments to aid in the risk assessment of critically ill patients on their first day of Intensive Care Unit (ICU) admission for progression to severe sepsis and septic shock.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

1 MOSES Clinical Trial Data. On file Thermo Fisher Scientific.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/multi-center-clinical-study-confirms-decreased-levels-of-procalcitonin-as-an-independent-predictor-of-mortality-in-patients-with-severe-sepsis-and-septic-shock-300441973.html


'/>"/>
SOURCE Thermo Fisher Scientific Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Inflamax Research Inc. Announces the Successful Completion of Enrollment for the First Multi-center, Mobile Environmental Exposure Chamber (mEEC™) Study
2. MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal
3. Benchmark Research/VaxCorps Named one of the Top Clinical Research Networks at ViE Awards
4. SimpleTrials Selected as a Top 10 eClinical Trial Management Solution Provider by Pharma Tech Outlook
5. Human Gene Therapy publishes review of randomized clinical trials of gene transfer for heart failure with reduced ejection fraction
6. 2-Day Seminar FDAs GMP Expectations for Phase I and First-in-Man Clinical Trials by Ex-FDA Official (Tampa, FL, United States - May 18-19, 2017) - Research and Markets
7. Keystone Nano Announces Start Of Clinical Testing Of Ceramide NanoLiposome For The Improved Treatment Of Cancer
8. Research Centers of America Adopts Verified Clinical Trials Biometrics Research Subject Database Registry to Prevent Duplicate Enrollment in Clinical Trials
9. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
10. Maxwell Biotech Venture Funds Portfolio Company Hepatera LLC Announces Completion of Recruitment for Phase 2b Clinical Trials of Myrcludex B in Chronic Hepatitis Delta
11. Amgen To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... ... nourishing a range of emerging bio and technology start-ups, is hosting “Celebration Friday” ... This double event will start with libations and networking at 3:30 p.m. at ...
(Date:4/20/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... prevention of migraine at the American Academy of Neurology ... 2017, in Boston . ... safety and patient outcomes data for galcanezumab in patients ... monthly migraine headache days among patients with episodic migraine. ...
(Date:4/20/2017)... Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the ... ("ILC") 2017 of the European Association for the Study of ... the positive effects of PBI-4050 on reduction of non-alcoholic steatohepatitis ... ... Gagnon, Vice-President of R&D Pre-clinical of Prometic "This extensive preclinical ...
(Date:4/20/2017)... 20, 2017 Dutch philosopher Koert van Mensvoort - ... the University of Technology in Eindhoven - has written a ,Letter to ... calls on humanity to avoid becoming a slave and victim to its own ... ... Dutch philosopher Koert van Mensvoort – founder of the Next Nature Network ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):